Stefania Vertuccio

Stefania Vertuccio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stefania Vertuccio has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improved Synthesis of 5-Nitrohomovanillic Acid and 6-Nitrohomovanillic Acid as Probes for Metabolism Studies of Endothelium-Derived Dopamines: Identification in Human Amniotic Fluid

    by Rosa Sparaco, Pierfrancesco Cinque, Antonia Scognamiglio, Stefania Vertuccio, Giuseppe Caliendo, Ferdinando Fiorino, Angela Corvino, Elisa Magli, Elisa Perissutti, Vincenzo Santagada, et al.

    6-Nitrodopamine is an endogenous catecholamine responsible for numerous biological activities. Here, an improved method for the synthesis of both 6-nitrohomovanillic acid (6-NHVA) and its regioisomer 5-nitrohomovanillic acid (5-NHVA) is reported. The developed one-step synthetic procedures ensured the efficient preparation of the target compounds in good yields. Comprehensive structural characterization was achieved through one- and two-dimensional NMR studies and by high-resolution mass spectrometry (HR-MS/MS). The presence of both substances was identified in human amniotic fluid by LC-MS/MS.


  • Open Access

    Quantitative analysis of pesticide residues in wine grapes during a downy mildew infestation using LC-MS/MS and associated risk assessment

    by Stefania Vertuccio, Marica Erminia Schiano, Chiara Cassiano, Lorenzo Marino Cerrato, Federica Sodano, Sabrina Pirozzi, Maria Grazia Rimoli, Elisa Perissutti, Ferdinando Fiorino, Vincenzo Santagada, et al.


  • Open Access

    1,2,4-Thiadiazolidin-3,5-Diones as Inhibitors of Cysteine Proteases

    by Maria Aparecida Juliano, Marco Persico, Beatrice Severino, Giuseppe Tumbarello, Debora Okamoto, Karolina Rosa Fernandes, Gabriel Trigo, Aparecida Sadae Tanaka, José Thalles Lacerda, Oleh Tkachuck, et al.

    A focused library of 1,2,4-thiadiazolidin-3,5-diones (THIA-1–10), previously characterized as hydrogen sulfide (H2S) donors, was evaluated for inhibitory activity against cysteine proteases. We included two key cysteine proteases aiming at antiviral drug development—SARS-CoV-2 3CLpro (Mpro) and PLpro—alongside reference enzymes Papain and Cathepsin L. The compounds exhibited distinct selectivity profiles and inhibition mechanisms. The ability to act as covalent inhibitors of 3CLpro in the nanomolar range is of particular interest, with compounds THIA-6, -7, and -10 proving to be the most potent inhibitors of the series, and compounds THIA-1, -2, and -8 proving to be the most selective with respect to the other proteases. We explored the molecular bases of the observed activity profile of THIA-1–10 through computational studies, which supported and complemented the experimental findings, paving the way for future structure optimization. The results highlight that inhibitory potency depends not only on electrophilicity but also on the ability to access the catalytic cysteine within the active site. The dual functionality of THIA-1–10 as H2S donors and selective cysteine protease inhibitors underscores its potential as a promising lead for therapeutic development.